.Pharmacolibrary.Drugs.ATC.J.J01DD52

Information

Ceftazidime is a third-generation cephalosporin antibiotic combined with a beta-lactamase inhibitor (such as avibactam) to increase effectiveness against resistant Gram-negative bacteria. It is mainly used for the treatment of serious bacterial infections including complicated urinary tract and intra-abdominal infections, and is currently approved for clinical use in many countries.

Pharmacokinetics

Pharmacokinetic parameters reported in healthy adult volunteers after intravenous administration of ceftazidime/avibactam (2 g/0.5 g).

References

1. Zhanel, GG, et al., & Karlowsky, JA (2019). Cefiderocol: A Siderophore Cephalosporin with Activity Against Carbapenem-Resistant and Multidrug-Resistant Gram-Negative Bacilli. Drugs 79(3) 271–289. DOI:10.1007/s40265-019-1055-2 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30712199

2. Sy, SKB, et al., & Derendorf, H (2019). Clinical Pharmacokinetics and Pharmacodynamics of Ceftazidime-Avibactam Combination: A Model-Informed Strategy for its Clinical Development. Clinical pharmacokinetics 58(5) 545–564. DOI:10.1007/s40262-018-0705-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/30097887

3. Al Jalali, V, et al., & Zeitlinger, M (2023). Plasma and intraperitoneal pharmacokinetics of ceftazidime/avibactam in peritoneal dialysis patients. Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 29(9) 1196.e1–1196.e7. DOI:10.1016/j.cmi.2023.06.002 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37301439

Revisions

• 06/2025 initial generated model